Exicure (XCUR) is capturing the attention of retail investors with a potential upside of
40.76%, as the stock trades at a last price of
4.23, showing a solid daily volume of
1.2M. With a Market Risk Adjusted Performance of
3.18, the excitement around this biotechnology company suggests that investors are optimistic about its future prospects.
Key Discoveries
Exicure's asset utilization reveals a concerning picture. The company is losing $0.002641 for every dollar of assets it holds, resulting in a negative utilization rate of -0.26 percent. This indicates that Exicure is not making the most of its resources, operating inefficiently with each dollar spent. In simpler terms, the company's performance raises red flags about its ability to generate profit from its assets. Investors should take note of this lackluster efficiency when considering Exicure's potential for growth.
The successful prediction of Exicure
stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published
stock prices of traded companies, such as Exicure, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at
the intrinsic value of Exicure based on Exicure hews, social hype, general headline patterns, and widely used
predictive technical indicators. We also calculate exposure to Exicure's
market risk, different
technical and
fundamental indicators, relevant financial multiples and ratios, and then
comparing them to Exicure's related companies.
Use Technical Analysis to project Exicure expected Price
Exicure technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Exicure technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Exicure trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions.
More Info...Exicure Gross Profit
Exicure Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Exicure previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Exicure Gross Profit growth over the last 10 years. Please check Exicure's
gross profit and other
fundamental indicators for more details.
Detailed Outlook On Exicure
The latest price spike of Exicure may raise some interest from retail investors as it is trading at a share price of
4.23 on
1,163,156 in trading volume. The company directors and management may have good odds in positioning the firm resources to exploit market volatility in
October. The stock standard deviation of daily returns for 90 days investing horizon is currently 17.95. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Exicure partners.
Current Deferred Revenue Breakdown
Exicure Current Deferred Revenue yearly trend continues to be relatively stable with very little volatility. Current Deferred Revenue is likely to drop to about 12.5
M. Current Deferred Revenue usually refers to revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. At this time, Exicure's Current Deferred Revenue is relatively stable compared to the past year.
| 2010 | 8.28 Million |
| 2017 | 1.03 Million |
| 2018 | 21.87 Million |
| 2020 | 8.34 Million |
| 2021 | 17.32 Million |
| 2023 | 19.91 Million |
| 2024 | 12.51 Million |
In the world of investing, perception can often be as powerful as reality. Exicure, Inc., a biotechnology firm based in Chicago, has recently caught the attention of retail investors, despite its lack of significant operations and a staggering probability of bankruptcy at 96.00%. The company's market capitalization stands at just $7.32 million, with a current valuation of $13.59 million, suggesting that investors are betting on potential rather than proven success. With insiders owning 58.73% of shares, confidence from those closest to the company may be a driving factor in retail interest. However, the company's financials reveal losses, including a return on assets of -0.26 and a return on equity of -1.44, raising questions about the sustainability of this hype.
Are Exicure technical ratios showing a throwback?
Exicure's stock is experiencing a significant change, with its expected shortfall dropping to -15.84 today. This decline suggests the stock may be entering a recovery phase after a period of volatility. Investors should pay attention to these technical indicators, as they could signal a chance to buy in before a potential price rebound. Currently, Exicure is facing considerable fluctuations in returns, which can help savvy investors time their moves. By understanding market volatility, traders can better assess the risks associated with Exicure's stock during both rising and falling markets.
Increased volatility, especially in bear markets, can pressure Exicure's stock price and lead investors to adjust their portfolios as they navigate price declines.Investing in Exicure stock could be an intriguing opportunity as we head into October. With an analyst consensus rating of "Strong Buy" and a potential upside price of
22.12, there’s a lot of excitement surrounding this company, especially given its focus on innovative nucleic acid therapies. The current market value sits around
4.23, which suggests that there could be significant room for growth. While the company does not have significant operations at the moment, the potential for breakthroughs in their field could lead to substantial returns for investors willing to take a chance. As always, it’s essential to weigh the risks and rewards carefully before diving in..
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time basis at the beginning of the pandemic and eventually acquired a real taste for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Exicure. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
[email protected]
